---
title: "Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286306276.md"
description: "Avalo Therapeutics, Inc. has seen its 12-month stock price target cut to $47.82, suggesting a potential upside of 144%. The average price target from 10 analysts has increased from $48.1 to $48.7, with estimates ranging from $35 to $62 per share. The consensus rating remains a \"Buy\" with 12 analysts recommending buys and none holding or selling. This information is based on the latest analyst forecasts and does not constitute investment advice."
datetime: "2026-05-13T19:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286306276.md)
  - [en](https://longbridge.com/en/news/286306276.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286306276.md)
---

# Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

-   According to estimates from 10 analysts, Avalo Therapeutics, Inc. stock's average price target has risen from $48.1 to $48.7, with forecasts ranging from $35 to $62 per share
-   Based on the May 12 closing price, the updated target implies approximately 144% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Avalo Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Avalo Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)